natgillin/translations-raw huggingface dataset:
10. meni, da je uspeh partnerstva odvisen od optimalne uporabe razpoložljivih sredstev glede na to, da do konca sedanjega finančnega okvira (2013) ni predvidenega dodatnega financiranja;
Considers that the success of the partnership, given the absence of additional funding before the end of the current financial framework (2013), depends on making optimum use of the available resources;
12. poziva Komisijo, naj se v zvezi z načrti za nadzor raka opre na ugotovitve partnerstva za preprečevanje in zdravljenje raka ter predloži predlog priporočila Sveta o načrtih za nadzor raka; poziva Komisijo, naj na letni ravni neodvisno spremlja izvajanje in napredek sprejetega priporočila;
Calls on the Commission to build on findings of the Cancer Partnership with regard to cancer control plans and to present a proposal for a Council Recommendation on Cancer Control Plans; calls on the Commission to monitor independently on a yearly basis the implementation and progress of the recommendation adopted;
20. poudarja vlogo presejanja kot enega najpomembnejših instrumentov v boju proti raku; poziva države članice, naj vlagajo v programe presejanja za odkrivanje raka, in meni, da so te pobude najučinkovitejše, če so redno na voljo najširšemu možnemu krogu ljudi;
Stresses the role of screening as one of the most important instruments in the fight against cancer; urges Member States to invest in cancer screening programmes and considers that these initiatives are most efficient when they are available to the widest possible range of people and on a regular basis;
27. poziva Komisijo, naj v sedmem okvirnem programu za raziskave zagotovi financiranje nadaljnjega razvoja krvnih in urinskih testov (testi z biomarkerji) in upošteva, da so ti postopki za zgodnje diagnosticiranje raka obetavno sredstvo za odkrivanje različnih vrst raka (prostate, debelega črevesa, jajčnikov, ledvic in mehurja);
Calls on the Commission to provide funding for the further development of blood- and urine-based tests (biomarker tests) within the seventh Research Framework Programme, bearing in mind that these early diagnosis procedures are promising tools for detecting different types of cancer (prostate, colon, ovarian, kidney, and bladder cancer);
31. poudarja, da češka vlada še ni ratificirala Okvirne konvencije SZO o nadzoru tobaka, ki je začela veljati februarja 2005, in jo poziva, naj to stori;
Notes that the Czech Government has not yet ratified the WHO Framework Convention on Tobacco Control, which entered into force in February 2005, and therefore urges it to do so;
40. meni, da sredstva, ki so zdaj na voljo za boj proti raku v EU, ne zadoščajo za potrebne raziskave in usklajevanje, niti za zagotovitev ustreznih informacij o preprečevanju za državljane EU;
Considers that the current funding available to fight cancer in the EU is inadequate to produce the necessary research and coordination as well as to provide decent preventive information for EU citizens;
44. poziva k reševanju težav, povezanih z okoljskim zdravjem, ki vplivajo na razvoj določenih vrst raka v skladu z opredelitvami v evropskem akcijskem načrtu za okolje in zdravje 2004–2010, in sicer z oceno poznejših nacionalnih akcijskih načrtov za okolje in zdravje ter sodelovanjem držav članic pri izmenjavi rezultatov, doseženih v procesu, da bodo lahko rezultati, pridobljeni v posameznih državah, spodbudili evropske ukrepe na tem področju;
Calls for the need to tackle environmental-health related problems which have impacts on the development of specific types of cancer in accordance with what has been defined under the European Environment and Health Action Plan 2004-2010, namely through the assessment of the subsequent national Environmental and Health Action Plans and through cooperation between Member States on the results achieved throughout the process, in order to guarantee that the results obtained in each country may help promote European intervention in this domain;
49. pozdravlja predlog Komisije o evropskem partnerstvu za boj proti raku za obdobje 2009–2013 in predlog, da se zmanjša breme raka z uvedbo presejalnih programov za raka dojke, materničnega vratu in debelega črevesa za vse prebivalstvo, ter poziva države članice, naj smernice v celoti izvajajo;
Welcomes the Commission proposal on a European Partnership for Action against Cancer for the period 2009-2013 and the proposal to reduce the cancer burden by introducing 100% population screening for breast, cervical and colorectal cancers by 2013, and urges Member States to fully implement the guidelines;
52. poziva Komisijo, naj v okviru partnerstva spodbuja in podpira pobude za preprečevanje uvoza izdelkov, ki vsebujejo rakotvorne kemikalije, in sprejme ukrepe na ravni EU za okrepitev preverjanj za odkrivanje takih kemikalij, ki bi bile lahko prisotne v živilih, vključno s pesticidi;
Calls on the Commission, working within the Partnership, to encourage and support initiatives seeking to prevent imports of goods containing cancer-producing chemicals, and to take Europe-wide measures with a view to intensifying checks to detect such chemicals, pesticides included, as might be present in foodstuffs;
57. meni, da predlagani strukturi manjka jasna opredelitev specifičnih ciljev ukrepov, na primer, kako do leta 2013 načrte vseh držav članic vključiti v boj proti raku, in poziva Komisijo, naj popravi to pomanjkanje medsebojne povezanosti;
Finds the proposed structure lacking since there is no clear definition of specific action objectives, such as how to achieve the integration of all Member States’ plans in the fight against cancer by 2013, and calls on the Commission to rectify this lack of focus;
60. poudarja, kako pomembna je revizija Direktive 2001/20/ES Evropskega parlamenta in Sveta z dne 4. aprila 2001 o približevanju zakonov in drugih predpisov držav članic v zvezi z izvajanjem dobre klinične prakse pri kliničnem preskušanju zdravil za ljudi (direktivo o kliničnih preskušanjih), da bi spodbudila več akademskih raziskav na področju raka, zlasti raziskave o preventivnih pregledih in zgodnjem odkrivanju rakavih obolenj, pri čemer naj upošteva stroške, povezane z neprofitnim raziskovalnim sektorjem, ter izboljša razpoložljivost informacij o kliničnih študijah, ki se izvajajo ali so že uspešno zaključene, za bolnike in širšo javnost;
Stresses the importance of the revision of Directive 2001/20/EC of the European Parliament and of the Council of 4 April 2001 on the approximation of the laws, regulations and administrative provisions of the Member States relating to the implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use (the Clinical Trials Directive) with a view to encouraging a greater cancer research effort, focusing in particular on screening, including early detection, without, however, disregarding the impact of the expenditure involved for the non-commercial research sector, and to improve the information available to patients and the public at large about clinical trials in progress or which have been successfully completed;
68. poudarja, da so cilji partnerstva EU pri preprečevanju in zdravljenju raka dolgoročni, zato poziva evropske institucije, naj v prihodnjem zdravstvenem proračunu Skupnosti podprejo njegovo delovanje za deset let; poziva Komisijo, naj oceni in spremlja napredek in učinkovitost pri izvajanju priporočil tega partnerstva ter enkrat letno poroča o svojih ugotovitvah;
Points out that the objectives set by the Cancer Partnership are long-term, and therefore urges the European institutions to support the 10-year sustainability and viability of the Cancer Partnership in a future Community health budget; calls on the Commission to assess, monitor and report on a yearly basis on progress and effectiveness in implementing the recommendations from the European Partnership;
Vsako leto diagnosticirajo raka pri 3,2 milijona Evropejcih
Every year 3.2 million Europeans are diagnosed with cancer
Kot je zapisano tudi sporočilu Komisije, je rak eden največjih zdravstvenih izzivov, s katerimi se soočamo v Evropi, pa tudi po svetu.
As the Commission Communication rightly states Cancer is one of the biggest health challenges we are facing in Europe and indeed worldwide.
Žal se obolevnost tudi v drugem tisočletju vrtoglavo veča.
Unfortunately, Cancer is still epidemically increasing in the second millennium.
Z več kot tremi milijoni novoobolelih in 1,7 smrti vsako leto je zdaj rak drugi najpogostejši vzrok smrti in obolevnosti v Evropi.
At present, with more than 3 million new cases and 1.7 million deaths each year, cancer represents the second most important cause of death and morbidity in Europe.
Po sedanjih podatkih bodo pri vsakem tretjem Evropejcu v življenju diagnosticirali raka, strokovnjaki pa predvidevajo, da bo to breme zaradi staranja prebivalstva strmo naraščalo, če ne bomo nemudoma ukrepali za nadzor te bolezni.
Currently one in three people in the EU will be diagnosed with cancer during their life-time and experts predict that the cancer burden will increase sharply due to the ageing population, unless urgent action to improve cancer control is taken now.
To je bil tudi razlog za resolucijo Evropskega parlamenta o boju proti raku v razširjeni EU, kampanjo parlamentarne interesne skupine Poslanci EP v boju proti raku, pobude slovenskega predsedovanja EU, zaradi katere je Svet sprejel sklepe o zmanjšanju bremena raka.
This was also the rationale for the European Parliament Resolution on combating cancer in the enlarged EU, the campaign of the Parliamentary Interest group MEPs against Cancer , the Slovenian EU Presidency initiative resulting in the adoption of the Council Conclusions on reducing the burden of cancer.
Odziv na te pobude je, da je rak še naprej posebna prednostna naloga Evropske skupnosti.
As a response to these initiatives, Cancer continues to be a special priority for the European Community.
Evropska komisija predlaga evropsko partnerstvo za boj proti raku za obdobje 2009–2013 , nov poskus, da bi v sodelovanju v duhu plodnega partnerstva združili vse zainteresirane strani.
The European Commission proposes a European Partnership for Action Against Cancer for the period 2009-2013 , a new essay to join all the stakeholders to work together in the spirit of fruitful partnership.
Rak je družbeno in politično vprašanje, zato zahteva skupno ukrepanje na evropski, nacionalni, regionalni in lokalni ravni.
Cancer is a social and political problem and therefore requires joint actions at European, national, regional and local level.
Lizbonska pogodba določa, da je Unija pristojna za izvajanje ukrepov za podporo, uskladitev ali dopolnitev ukrepov držav članic.
The Lisbon Treaty defines precisely that the Union shall have competence to carry out actions to support, coordinate or supplement the actions of the Member States.
Eno od področij tovrstnega ukrepanja je varstvo in izboljšanje človekovega zdravja (člen 2E).
One of the areas of such action, at European level, is protection and improvement of human health (Article 2E).
V času finančne krize ima evropsko partnerstvo odlično priložnost, da spodbudi države članice, naj več vlagajo v preprečevanje in zdrav način življenja.
In the time of financial crisis, the European Partnership has a great opportunity to encourage Member States to invest more in the prevention and healthy lifestyle.
Da bi učinkoviteje usklajevali dejavnosti in ukrepe, ki jih države članice in druge zainteresirane strani sprejemajo na različnih področjih politike, moramo ves čas tesno sodelovati z delodajalci in delavci.
To more effectively coordinate activities and actions that are taken within different policy areas by Member States and other stakeholders, we have to consistently cooperate closer with employers and employees.
Evropsko breme raka bomo znatno zmanjšali samo, če bomo k skupnim prizadevanjem pritegnili ustrezne zainteresirane strani po vsej Evropski uniji.
Only by engaging relevant stakeholders across the European Union in a collective effort to address cancer, we can remarkably reduce the European burden of cancer.
Rak je eno najbolj dolgoročnih področij ukrepanja Skupnosti v javnem zdravju.
Cancer is one of the most long-standing areas of Community action in the field of public health.
V zdravstveni politiki na ravni EU je bilo doseženega že veliko, kar posredno in neposredno vpliva na preprečevanje in nadzor raka.
Much has been achieved in health policy at the EU level in several domains which have a direct and positive impact on cancer prevention and control.
Evropski parlament je bil v svojem prejšnjem mandatu na tem področju zelo dejaven.
In its previous mandate, the European Parliament was very active in this spirit.
Vprašanje raka nam je uspelo postaviti kot prednostno na dnevni red evropskih institucij.
We managed to put cancer issue higher on the political agenda of the European institutions.
V Evropi pa vendarle še vedno vladajo nesprejemljive razlike v obvladovanju raka.
But Europe is still characterised by unacceptable inequalities in cancer control.
Zato so EU in nekatere države začele več projektov, med drugim programe zgodnjega odkrivanja raka in nacionalne načrte za raka.
For this reason the EU as well as national states have launched several projects including Cancer Screening Programmes and National Cancer Plans.
Dobro zasnovan in voden program za nadzor raka zmanjša pojavnost te bolezni in izboljša življenje bolnikov z rakavimi obolenji, ne glede na to, s kako omejenimi sredstvi razpolagajo države.
A well-conceived, well-managed national cancer control programme lowers cancer incidence and improves the life of cancer patients, no matter what resource constraints a country faces.
Zato bi moral biti eden najpomembnejših ukrepov partnerstva pozvati vlade in EU k razvoju, izvajanju in izboljšanju že obstoječih nacionalnih načrtov za raka.
Therefore, one of the most important Partnership actions should be to call on all governments in the EU to develop, implement and, where already existing, improve national cancer plans.
Tovrstni načrti bi se morali spoprijeti s temi obolenji na vseh ravneh – od preprečevanja, presejalnih pregledov in zgodnjega odkrivanja do vrhunske diagnostike, zdravljenja in nege, psihosocialne in paliativne oskrbe, pa tudi raziskav rakavih obolenj.
Such plans should tackle the disease on all fronts – from prevention, screening and early detection to top-quality diagnostics and treatment and care, psychosocial and palliative care and include cancer research.
Evropsko partnerstvo določa, da se da tretjina rakavih obolenj preprečiti in da je preprečevanje stroškovno najučinkovitejši ukrep.
The European Partnership states that one third of cancers are preventable and that prevention is the most cost-effective response.
Ukrepanje v tej smeri pa zahteva dolgoročno in nenehno vlaganje.
However, this requires a long-term and sustainable investment for action.
Če želi Evropa izpolniti ambiciozni cilj, ki ga je Komisija zastavila v svojem sporočilu, namreč 15-odstotno zmanjšanje novoobolelih do leta 2020, in če upoštevamo naraščajoči trend rasti in staranja prebivalstva, bi morali zagotovo znižati stopnje pojavnosti.
If Europe wants to meet the ambitious target set by the Commission Communication of a 15 % reduction of new cancer cases by 2020 and, in light of the present upward trend due to population growth and ageing, incidence rates would have to fall to meet this target.
Zato pozivamo, naj se v preprečevanje sistematično in strateško vlaga več sredstev, sicer bo zastavljeni cilj ostal povsem nestvaren.
We therefore urge that more resources are systematically and strategically invested in prevention, otherwise this target may remain a dream.
Priporočamo, naj se ta instrumenta v okviru partnerstva odločneje spodbujata, da bi zajeli čim širšo javnost, tudi težje dosegljive kroge, na primer manjšine in prikrajšane skupine.
Our recommendation is that these existing instruments be more forcefully promoted under the Partnership to mobilise wide sectors of the general public, including the more difficult to reach circles such as minority and disadvantaged groups.
Eden od izzivov pri argumentiranju preprečevanja je, da moramo vlagati v prihodnost, saj je za pobude glede preventivnih dejavnosti že zaradi njihove narave potrebnih vsaj deset let, da se pokažejo oprijemljivi rezultati.
One of the challenges when arguing the case of prevention is that we must commit to invest in the future as any prevention initiative will by its very nature have a time span of 10 years to bring measurable results.
Sistematično moramo zbirati dokaze o preprečevanju, sicer bo prepričevanje vlad, naj vlagajo vanj, nenehno Sizifovo delo.
We need to gather systematically the evidence for prevention otherwise there will be a continued uphill struggle to convince national governments to invest in prevention.
V tem smislu je ena od pomanjkljivosti predloga Komisije, da so cilji v njenem sporočilu zastavljeni za desetletno obdobje, proračun Skupnosti pa je organiziran kratkoročno.
In this respect one of the weaknesses of the Commission proposal is that the Communication sets targets for a 10 year time span while the financial support through the Community budget is organised on a short-term basis.
Predlagamo, naj se poročilo predstavi odboru ENVI Evropskega parlamenta v tretjem letu delovanja partnerstva, da se bodo sprejeti ukrepi pregledali in da se bo zagotovila nadaljnja proračunska podpora naše institucije.
We suggest that a report be presented in the third year of the Partnership’s activity to the European Parliament’s ENVI Committee to review the actions taken to rally further budgetary support by our institution.
Odbor za industrijo, raziskave in energetiko poziva Odbor za okolje, javno zdravje in varnost hrane, kot pristojni odbor, da v svoj predlog resolucije vključi naslednje pobude:
The Committee on Industry, Research and Energy calls on the Committee on the Environment, Public Health and Food Safety, as the committee responsible, to incorporate the following suggestions in its motion for a resolution:
A. ob upoštevanju svoje resolucije z dne 10. aprila 2008 o boju proti raku v razširjeni Evropski uniji
A. having regard to its resolution of 10 April 2008 on combating cancer in the enlarged European Union
1. pozdravlja sporočilo Komisije z naslovom Boj proti raku: evropsko partnerstvo ( KOM(2009)0291 ) in namero, da se vzpostavi partnerstvo, ki bo omogočalo izmenjavo informacij, znanja in dobre prakse;
Welcomes the Commission communication entitled ‘Action Against Cancer: European Partnership’ ( COM(2009)0291 ) and the proposal to establish a partnership for the exchange of information, skills and good practices;
3. meni, da je uspeh partnerstva odvisen od optimalne uporabe razpoložljivih sredstev glede na to, da do konca sedanjega finančnega okvira (2013) ni predvidenega dodatnega financiranja;
Considers that the success of the partnership, given the absence of additional funding before the end of the current financial framework (2013), depends on making optimum use of the available resources;
13. meni, da predlagani strukturi manjka jasna opredelitev specifičnih ciljev ukrepov, na primer, kako do leta 2013 načrte vseh držav članic vključiti v boj proti raku, in poziva Komisijo, naj popravi to pomanjkanje medsebojne povezanosti;
Finds the proposed structure lacking since there is no clear definition of specific action objectives, such as how to achieve the integration of all Member States’ plans in the fight against cancer by 2013, and calls on the Commission to rectify this lack of focus;
Direktiva 2001/20/ES Evropskega parlamenta in Sveta z dne 4. aprila 2001 o približevanju zakonov in drugih predpisov držav članic v zvezi z izvajanjem dobre klinične prakse pri kliničnem preskušanju zdravil za ljudi (UL L 121, 1.5.2001, str.
Directive 2001/20/EC of the European Parliament and of the Council of 4 April 2001 on the approximation of the laws, regulations and administrative provisions of the Member States relating to the implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use (OJ L 121, 1.5.2001, p.
34). , da bi bolj spodbujala raziskave o raku, zlasti o presejalnih programih;
34). with a view to encouraging a greater research effort on cancer, and in particular on screening;
António Fernando Correia De Campos, Ilda Figueiredo, Françoise Grossetête, Yannick Jadot, Oriol Junqueras Vies, Ivailo Kalfin, Silvana Koch-Mehrin, Bernd Lange, Alajos Mészáros, Tiziano Motti, Vladko Todorov Panajotov (Vladko Todorov Panayotov), Silvia-Adriana Ţicău, Hermann Winkler
António Fernando Correia De Campos, Ilda Figueiredo, Françoise Grossetête, Yannick Jadot, Oriol Junqueras Vies, Ivailo Kalfin, Silvana Koch-Mehrin, Bernd Lange, Alajos Mészáros, Tiziano Motti, Vladko Todorov Panayotov, Silvia-Adriana Ţicău, Hermann Winkler
o sporočilu Komisije o boju proti raku: evropsko partnerstvo
on the Commission communication on Action against Cancer: European Partnership
– ob upoštevanju člena 168 Pogodbe o delovanju Evropske unije, ki se nanaša na zdravstvene politike,
– having regard to Article 168 of the Treaty on the Functioning of the European Union, concerning health policies,
– ob upoštevanju programa javnega zdravja za obdobje 2007–2013, ki je osredinjen na sredstva in metode za reševanje zdravstvenih težav,
– having regard to the 2007-2013 public health programme, which focuses on the means and methods of tackling health problems,
– ob upoštevanju četrte izdaje evropskih smernic za zagotavljanje kakovosti pri presejalnih programih in diagnosticiranju raka dojke, ki jih je pripravila Komisija
– having regard to the fourth edition of the Commission’s European guidelines for quality assurance in breast cancer screening and diagnosis
Evropske smernice za zagotavljanje kakovosti pri presejalnih programih in diagnosticiranju raka dojke.
European guidelines for quality assurance in breast cancer screening and diagnosis.
Četrta izdaja, Evropska Komisija, Generalni direktorat za zdravje in varstvo potrošnikov, 2006. ,
Fourth edition, European Commission, Director General for Health and Consumer Protection, 2006. ,
– ob upoštevanju svojih resolucij o boju proti raku z dne 10. aprila 2008
– having regard to its resolutions on combating cancer of 10 April 2008
P6_TA(2008)0121 in o raku dojk z dne 25. oktobra 2006
P6_TA(2008)0121 and on breast cancer of 25 October 2006
– ob upoštevanju priporočila Sveta o presejalnih pregledih za odkrivanje raka z dne 2. decembra 2003 in njegovega sklepa o zmanjšanju bremena raka z dne 22. maja 2008,
– having regard to the Council’s recommendation of 2 December 2003 on cancer screening as well as to the Council’s conclusions on reducing the burden of cancer of 22 May 2008,
A. ker je rak po besedah Svetovne zdravstvene organizacije eden glavnih vzrokov smrti v svetu, leta 2004 pa je povzročil okrog 13 % vseh smrti,
A. whereas, according to the World Health Organisation, cancer is one of the leading causes of death worldwide and accounted for around 13% of all deaths in 2004,
B. ker je bil po letnem poročilu Eurostata v obdobju 2006–2007 rak eden glavnih vzrokov smrti v EU-25, saj je letno zahteval več kot milijon življenj,
B. whereas, according to the Eurostat yearbook for 2006-2007, cancer is one of the main causes of death in the EU-25, claiming more than 1 million lives per year,
C. ker sta preprečevanje raka ter dostopnost zgodnjega presejalnega pregleda in diagnoze najpomembnejša pogoja za učinkovito spoprijemanje z bremenom raka,
C. whereas prevention and access to early screening and diagnosis are the most important prerequisites for effectively addressing the burden of cancer,